Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optic nerve perfusion after panretinal photocoagulation versus ranibizumab for high-risk proliferative diabetic retinopathy
PACTR202206535473146Unknown
- Sponsor
- Ain Shams University Hospitals
- Start
- Jul 2019
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Ain Shams University Hospitals. Primary endpoint: Peripapillary vascular density. Status: unknown.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on PACTR202206535473146.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202206535473146.